{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"description":"Neutrophil engraftment is defined as ANC ≥ 0.5 × 10\\^9/L × 3 consecutive daily assessments. The first of 3 consecutive days for which ANC ≥ 0.5 × 109/L will be recorded as the date of neutrophil engraftment. Time to neutrophil engraftment will be calculated as the time from the date of the ASCT to the date of neutrophil engraftment.","groups":[{"description":"Granix on Day -7 through Day -2.\n\nHDM intravenously (IV) on Day -2.\n\nAutologous stem cell transplantation on Day 0","id":"OG000","title":"Experimental: Granix and High Dose Melphalan (HDM)"},{"description":"HDM intravenously (IV) on Day -2.","id":"OG001","title":"Control: High Dose Melphalan (HDM)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to Day 30","title":"Number of Participants With Neutrophil Engraftment","type":"SECONDARY","unitOfMeasure":"Participants"}